<DOC>
	<DOCNO>NCT00250276</DOCNO>
	<brief_summary>Human papillomavirus infection clearly recognize cause cervical cancer . Indeed , infection cervix certain oncogenic type HPV , clear , lead time cervical cancer woman . This study compare immune response induce different lot HPV-16/18 L1/AS04 vaccine , follow adjustment manufacture process .</brief_summary>
	<brief_title>Evaluation Immune Responses GSK Biologicals ' HPV Vaccine Following Manufacturing Process Adaptation .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female subject , include , 18 25 year age time first vaccination . Written inform consent obtain subject prior enrolment . Subject must negative urine pregnancy test . Healthy subject enter study entry establish medical history physical examination . Subject must nonchildbearing potential . pregnant breastfeeding subject . previous vaccination human papillomavirus ( HPV ) . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality . History chronic condition ( ) require treatment cancer , chronic hepatic kidney disease ( ) , diabetes autoimmune disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>